Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5104759 | Value in Health | 2017 | 7 Pages |
Abstract
Hemophilia A is a rare disease with a low prevalence; therefore, the overall cost to society of introducing rFVIIIFc is small. Considerations for comprehensively assessing the budget impact of introducing rFVIIIFc should include episodic and prophylaxis regimens, bleed avoidance, and annual factor consumption required under alternative scenarios.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Suzanne MPH, Brieana PharmD, Eric PhD, Jon PharmD, Karissa PhD,